ZOLL Medical Corporation (ZOLL), has received approval from the US Food and Drug Administration (FDA) to market and sell a new model of the LifeVest wearable defibrillator.
The LifeVest wearable defibrillator is worn by patients at risk for sudden cardiac arrest (SCA), allowing their physicians time to assess their long-term arrhythmic risk and make appropriate plans, including potentially the decision to implant a cardioverter defibrillator (ICD). The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living.
“With the FDA approval of this additional LifeVest model, we are increasing inventory levels to provide improved customer service to support our continued growth,” said Richard A. Packer, Chairman and Chief Executive Officer of ZOLL. Mr. Packer said: “We are pleased to be able to focus on meeting physicians’ needs for this lifesaving therapy for their patients.”
The LifeVest is rented to patients like other durable medical equipment (DME), allowing physicians to provide the patient the protection of the LifeVest by placing a medical order directly with ZOLL. From this point, ZOLL manages the process to protect the patient from sudden cardiac arrest from hospital discharge to recovery at home, including fitting the LifeVest to the patient, educating the patient in the hospital prior to release, managing all of medical documentation and insurance paperwork, and addressing via telephone and in person any patient needs once home.